Biotech Funding Crisis Forces Strategic Pivots as VC Investment Remains Challenging Despite Recovery Signs
核心洞察
Biotech companies face a challenging funding environment in 2025, with GlobalData (搜索) reporting a 5% contraction in year-on-year deal value during the first four months, forcing difficult strategic decisions about asset prioritization.
Despite venture capital financing recovering to $34 billion in 2024 (a 15% increase from the previous year), early-stage biotechs struggle with limited access to capital, with discovery and preclinical-stage companies seeing IPO values drop four-fold from $490.6 million in 2023 to $112.5 million in 2024.
The selective investment climate has led to fewer but higher-value deals, with pharmaceutical companies spending a record $108 billion on licensing agreements in 2024 across only 257 deals compared to an average of 429 deals between 2015-2020.
The biotech funding landscape remains challenging in 2025, with early-stage companies struggling to secure capital needed for drug development programs. GlobalData (搜索) recently reported a 5% contraction in year-on-year deal value during the first four months of 2025, primarily driven by declining mergers and acquisitions activity.
"The current financial market is tough, and biotechs are finding it very difficult to get access to capital," comments Samir Kagrana, Global Head of Strategic Deals at Fortrea (搜索), a contract research organization. "It takes at least ten years to develop a molecule, and that development is becoming more and more complex and expensive over time."
The funding constraints are forcing biotechs to make difficult strategic decisions about asset prioritization. "Many biotechs are struggling to realise the full potential of the intellectual properties that they have, which not only impacts the biotech's survival but also the industry as a whole," Kagrana explains. "Even if they do secure funds, they may not have enough for the parallel development of multiple assets, so they need to prioritise the most promising one out of three or four potential therapies."
Recovery Following 2021 Boom and Bust Cycle
The current challenges stem from the aftermath of the 2021 biotech boom, when favorable economic conditions and COVID-19 pandemic response led to record-high investment levels. According to GlobalData (搜索)'s Deals database, pharmaceutical venture capital deals reached almost $70 billion in 2021, representing a considerable leap from previous years.
The subsequent sharp decline in 2022 and 2023 was compounded by many companies going public with inflated valuations, contributing to a more cautious investment environment. High interest rates and inflation forced many start-ups to delay their IPOs until market conditions improved.
Venture financing has shown signs of recovery, with the value of all VC arrangements in the industry increasing by almost 15% from the previous year to $34 billion in 2024 – higher than pre-pandemic figures. Biopharma IPOs also saw an upturn, with 50 completed IPOs raising a total of $8.52 billion, representing a 68% increase from 2023.
Shift Toward Later-Stage Companies
Despite overall IPO value increases, early-stage companies face particular challenges. Alison Labya, Business Fundamentals Analyst at GlobalData (搜索), explains: "Despite the overall increase in IPO value raised, discovery and preclinical-stage companies saw a four-fold drop in total IPO value from $490.6 million in 2023 to $112.5 million in 2024, indicating a shift in public investor preference towards more advanced stage companies."
GlobalData (搜索) analysts noted a recent trend towards high-value IPOs involving more established companies, leaving early-stage firms in a difficult position. This selective approach is mirrored in industry partnerships, with pharmaceutical companies spending $108 billion on licensing agreements in 2024 – the highest amount across the past decade – but distributed across fewer deals than normal.
The average number of licensing agreement deals between 2015 and 2020 was 429, while 2023 saw 308 deals, followed by 257 in 2024. This means that while pharma is spending more on acquiring biotech assets, fewer acquisitions are being made overall.
Strategic Adaptations and Virtual Models
The challenging funding environment has prompted biotechs to explore alternative operating models. Virtual biotechs, sometimes called "backyard biotechs," are gaining popularity as a way to offset limited funds. These organizations often focus on rarer and more neglected diseases, finding markets for compounds where blockbusters and biosimilars are not feasible for smaller biotech organizations.
The relationship between small biotech and big pharma continues to evolve, with some industry observers questioning whether mergers and acquisitions benefit biotech firms in the long run. Some biotechs are considering maintaining independence or seeking partners that will retain biotech culture and treat relationships more as partnerships rather than acquisitions.
Improving Industry Sentiment
Despite ongoing challenges, optimism levels are gradually improving within the industry. In a GlobalData (搜索) survey conducted in late 2023, 44% of industry professionals were optimistic about a recovery of biotech funding. The same survey conducted one year later showed this figure increased to 50%.
In the current selective investment climate, strong and compelling value propositions are essential for persuading investors and potential licensing partners. Emerging biotechs need well-crafted strategies for prioritizing assets, navigating investment opportunities, and fine-tuning commercial positioning.
Collaborations with contract research organizations are becoming increasingly important, as CROs can provide end-to-end services to help biotechs with limited internal resources gain access to expertise needed for clinical development, asset prioritization, funding opportunities, and regulatory pathways.